Pfizer Advances Avelumab In Ovarian Cancer With Syndax Combo Deal
This article was originally published in The Pink Sheet Daily
Phase I/II trial will combine Syndax's entinostat, an HDAC inhibitor, with Pfizer/Merck KGaA's PD-L1 inhibitor avelumab. The antibody is the first immunotherapy to reach Phase III in platinum-resistant/refractory ovarian cancer.
You may also be interested in...
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.